Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum]

Published Erratum

Q Yin et al. Drug Des Devel Ther. 2015.

. 2015 Nov 6:9:5947.

doi: 10.2147/DDDT.S98298. eCollection 2015.

No abstract available

Erratum for

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.
Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H, Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C. Yin Q, et al. Drug Des Devel Ther. 2015 Sep 30;9:5407-19. doi: 10.2147/DDDT.S92041. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26491252 Free PMC article.

A novel treatment for refractory primary biliary cirrhosis?
Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H, Ishii H. Miyaguchi S, et al. Hepatogastroenterology. 2000 Nov-Dec;47(36):1518-21. Hepatogastroenterology. 2000. PMID: 11148991
Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
Lens S, Leoz M, Nazal L, Bruguera M, Parés A. Lens S, et al. Liver Int. 2014 Feb;34(2):197-203. doi: 10.1111/liv.12290. Epub 2013 Sep 2. Liver Int. 2014. PMID: 23998489
Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
Takeuchi Y, Ikeda F, Fujioka S, Takaki T, Osawa T, Yasunaka T, Miyake Y, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K, Itoshima T. Takeuchi Y, et al. J Gastroenterol Hepatol. 2011 Sep;26(9):1395-401. doi: 10.1111/j.1440-1746.2011.06737.x. J Gastroenterol Hepatol. 2011. PMID: 21443659
[Possibilities in the treatment of primary biliary cirrhosis].
Lengyel G, Tulassay Z. Lengyel G, et al. Orv Hetil. 2005 Jun 5;146(23):1245-9. Orv Hetil. 2005. PMID: 15988919 Review. Hungarian.
Primary biliary cirrhosis.
Carey EJ, Ali AH, Lindor KD. Carey EJ, et al. Lancet. 2015 Oct 17;386(10003):1565-75. doi: 10.1016/S0140-6736(15)00154-3. Epub 2015 Sep 11. Lancet. 2015. PMID: 26364546 Review.